These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11861803)

  • 1. Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor.
    Graff J; Klinkhardt U; Schini-Kerth VB; Harder S; Franz N; Bassus S; Kirchmaier CM
    J Pharmacol Exp Ther; 2002 Mar; 300(3):952-7. PubMed ID: 11861803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.
    Graff J; Andries D; Elsner M; Westrup D; Bassus S; Franz N; Klinkhardt U; Harder S
    Br J Clin Pharmacol; 2001 Jun; 51(6):577-82. PubMed ID: 11422017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model.
    Klinkhardt U; Graff J; Harder S
    Clin Pharmacol Ther; 2002 Mar; 71(3):176-85. PubMed ID: 11907492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ; Taatjes DJ; Sobel BE
    Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U; Kirchmaier CM; Westrup D; Graff J; Mahnel R; Breddin HK; Harder S
    Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet alpha-granule secretion and its modification by SC-57101A, a GPIIb/IIIa antagonist.
    Ogawa T; Sugidachi A; Otsuguro K; Isobe T; Asai F
    Biochem Pharmacol; 2002 May; 63(10):1911-8. PubMed ID: 12034376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters.
    Klinkhardt U; Kirchmaier CM; Westrup D; Breddin HK; Mahnel R; Graff J; Hild M; Harder S
    Thromb Res; 2000 Feb; 97(4):201-7. PubMed ID: 10674406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive therapy regimen and platelet activation in renal transplant patients.
    Graff J; Klinkhardt U; Harder S; Wegert W; Lenz T; Scheuermann EH; Gossmann J
    Clin Pharmacol Ther; 2002 Oct; 72(4):411-8. PubMed ID: 12386643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
    Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
    Graff J; Klinkhardt U; Harder S
    Thromb Res; 2004; 113(5):295-302. PubMed ID: 15183041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel.
    Gremmel T; Eslam RB; Koppensteiner R; Lang IM; Panzer S
    Cardiovasc Ther; 2013 Oct; 31(5):e40-5. PubMed ID: 23311679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein phosphatase inhibitor calyculin-A modulates activation markers in TRAP-stimulated human platelets.
    Simon Z; Kiss A; Erdödi F; Setiadi H; Beke Debreceni I; Nagy B; Kappelmayer J
    Platelets; 2010; 21(7):555-62. PubMed ID: 20670106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
    Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
    Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting.
    Massberg S; Mueller I; Besta F; Thomas P; Gawaz M
    Am Heart J; 2003 Nov; 146(5):E19. PubMed ID: 14597948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating effects of GPIIb/IIIa blockers: an intrinsic consequence of ligand-mimetic properties.
    Peter K; Schwarz M; Bode C
    Circulation; 2002 May; 105(21):E180-1. PubMed ID: 12034670
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.